18 stories
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Physician-journalist Dhruv Khullar traces the peptide movement from CrossFit communities to mainstream wellness, documenting contamination (lead in BPC-157, endotoxins in TB-500), lack of human trials, and RFK Jr.'s attacks on FDA restrictions.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A physician essays about a patient who stopped her statin despite high coronary calcium yet continues injecting BPC-157 ordered online, highlighting the growing trust gap between consumer-hyped peptides and evidence-backed medications.
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'
Updated explainer clarifying BPC-157 is not outright banned but in Category 2 requiring further investigation. Discusses potential shifts after public statements about moving peptides back to Category 1.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.
Health Secretary Kennedy announced on Joe Rogan's podcast that the FDA will soon reclassify about 14 peptides currently restricted from compounding pharmacies, aiming to curb gray-market sourcing.
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.